TTK Healthcare Ltd. Stock Falls to 52-Week Low of Rs.925

Stock Price Movement and Market Context

On 16 Feb 2026, TTK Healthcare’s share price touched Rs.925, marking its lowest level in the past 52 weeks. This decline comes despite the broader market’s positive momentum, with the Sensex closing at 82,867.80, up 0.29% after recovering from an early negative opening. The Sensex remains within 3.97% of its 52-week high of 86,159.02, supported by strong performances from mega-cap stocks. In contrast, TTK Healthcare’s stock has underperformed significantly, declining by 20.51% over the last year compared to the Sensex’s 9.13% gain.

TTK Healthcare’s share price is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning indicates sustained selling pressure and a lack of upward momentum in the near term. Notably, the stock has shown a slight recovery after two consecutive days of decline, but remains well below its 52-week high of Rs.1402.

Financial Performance and Growth Trends

Over the past five years, TTK Healthcare has exhibited modest growth, with net sales increasing at an annualised rate of 6.99% and operating profit growing at 15.42%. While these figures indicate some expansion, they fall short of robust growth benchmarks expected in the diversified sector. The company’s return on equity (ROE) stands at 6.5%, reflecting moderate profitability relative to shareholder equity.

Recent quarterly results have been largely flat, with non-operating income constituting a substantial 80.43% of profit before tax (PBT), suggesting limited contribution from core business activities. Additionally, the company’s cash and cash equivalents at the half-year mark were recorded at Rs.600.89 crores, the lowest level in recent periods, which may constrain liquidity flexibility.

Operational Efficiency and Receivables Management

The company’s debtor turnover ratio at half-year stands at 7.40 times, the lowest recorded in recent periods. This metric indicates slower collection of receivables, which can impact working capital management and cash flow. Despite a low average debt-to-equity ratio of zero, signalling minimal leverage, the company’s ability to generate cash from operations remains a concern given the receivables cycle.

Valuation and Market Perception

TTK Healthcare’s stock trades at a price-to-book value of 1.2, which is a premium relative to its peers’ historical averages. The company’s price-to-earnings-to-growth (PEG) ratio is notably high at 8.1, reflecting a valuation that may not be fully supported by its earnings growth, which has risen by only 2.4% over the past year. This disparity between valuation and growth metrics may contribute to subdued market enthusiasm.

Domestic mutual funds hold a minimal stake of just 0.01% in TTK Healthcare, a factor that may reflect limited institutional conviction. Given their capacity for detailed research and on-the-ground analysis, this small holding could indicate reservations about the company’s current valuation or business prospects.

Comparative Performance and Market Standing

Over the last three years, TTK Healthcare has underperformed the BSE500 index across multiple time frames, including one year and three months. The stock’s total return over the past year is negative 21.86%, further underscoring its relative weakness within the diversified sector. This underperformance contrasts with the broader market’s positive trajectory and highlights challenges in sustaining investor confidence.

Mojo Score and Analyst Ratings

TTK Healthcare currently holds a Mojo Score of 37.0, categorised as a Sell grade. This rating was downgraded from Hold on 21 Jul 2025, reflecting a reassessment of the company’s growth prospects and financial health. The market capitalisation grade stands at 4, indicating a mid-tier valuation relative to market peers. The stock’s day change on the latest trading session was a decline of 0.84%, in line with sector performance.

Summary of Key Metrics

To summarise, TTK Healthcare’s key financial and market indicators as of early 2026 include:

• 52-week low price: Rs.925
• 52-week high price: Rs.1402
• One-year stock return: -20.51%
• Net sales growth (5 years CAGR): 6.99%
• Operating profit growth (5 years CAGR): 15.42%
• ROE: 6.5%
• Price to Book Value: 1.2
• PEG ratio: 8.1
• Cash and cash equivalents (HY): Rs.600.89 crores
• Debtor turnover ratio (HY): 7.40 times
• Non-operating income as % of PBT (Q): 80.43%
• Mojo Grade: Sell (downgraded from Hold)

These figures illustrate a company facing headwinds in both growth and valuation metrics, contributing to its recent share price decline and 52-week low.

Market Environment and Sector Comparison

While the broader diversified sector and mega-cap stocks have shown resilience and gains in recent months, TTK Healthcare’s performance remains subdued. The stock’s trading below all major moving averages contrasts with the Sensex’s position, where the 50-day moving average remains above the 200-day moving average, signalling a generally positive market trend. This divergence highlights the stock’s relative weakness within its sector and the wider market.

Conclusion

TTK Healthcare Ltd.’s fall to a 52-week low of Rs.925 reflects a combination of modest growth rates, valuation premiums not fully supported by earnings, and limited institutional interest. Despite a low debt profile and moderate profitability, the company’s recent financial indicators and market performance suggest ongoing challenges in regaining upward momentum. The stock’s current technical and fundamental positioning underscores the cautious stance reflected in its Mojo Sell rating and recent downgrade.

Unlock special upgrade rates for a limited period. Start Saving Now →